Jul 16, 2025
Users
🦶 The $3.5 Billion Ulcer Problem: Can Hydrogels Fix Chronic Wounds?
Sinan Gölhan
Founder & CEO at GelTech Labs
Chronic wounds don’t just hurt — they cost lives.
Every year, over 9 million people suffer from diabetic foot ulcers (DFUs), venous leg ulcers, or pressure sores that resist healing. These wounds are painful, infection-prone, and extremely costly — both to patients and healthcare systems.
In the U.S. alone, DFUs contribute to $3.5 billion in direct costs annually, and are responsible for more hospitalizations than any other diabetes-related complication (Source: NIH).
Despite this, most treatments haven’t evolved past basic dressings. But a new class of materials — bioactive hydrogels — may offer a way forward.
Why Chronic Wounds Don’t Heal
Chronic wounds get stuck in a dysfunctional inflammatory cycle, which leads to:
Prolonged inflammation
Poor blood vessel formation (angiogenesis)
Reduced fibroblast and keratinocyte activity
Persistent infection and biofilm formation
To break the cycle, new wound care materials need to be more than absorbent — they need to be dynamic and therapeutic. That’s where hydrogels excel.
Hydrogels as Bioactive Healers
Next-generation hydrogel dressings are being engineered to do more than just cover a wound:
🧪 Anti-inflammatory action Hydrogels incorporating curcumin, resveratrol, or IL-10 have shown strong results in suppressing inflammatory cytokines and speeding healing (Chen et al., Advanced Functional Materials, 2022).
💉 Angiogenesis promotion VEGF-loaded hydrogels are being studied for their ability to stimulate new blood vessel formation in ischemic wounds (Tang et al., Bioactive Materials, 2021).
🛡️ Antibacterial protection Antimicrobial hydrogel dressings using silver nanoparticles, chitosan, or responsive pH triggers are effective against common pathogens without promoting resistance (Zhang et al., Materials Today Bio, 2020).
💊 Smart release systems Hydrogels with controlled swelling or enzymatically triggered degradation offer programmable drug release that aligns with wound healing timelines.
Who’s Leading the Charge?
Several products and platforms are moving from lab to clinic:
Hydrofera Blue — A polyurethane foam infused with methylene blue and gentian violet, used widely in chronic wound clinics for antimicrobial coverage with hydrogel-like performance.
Chalmers University of Technology — Swedish researchers developed a hydrogel that releases hydrogen peroxide at wound sites. Early results suggest dual action: disinfection and stimulation of tissue regeneration.
Cresilon — Backed by over $30M in funding, they’ve developed a hemostatic hydrogel (VETIGEL®) with potential expansion into chronic care markets like pressure ulcers.
Axio Biosolutions — Their chitosan-based hydrogel dressing (MaxioCel®) is CE-certified and approved for managing chronic wounds in India and Europe, showing real-world clinical traction.
So… Can Hydrogels Solve It?
They’re not a silver bullet — chronic wounds are multifactorial, and success depends on patient condition, comorbidities, and care environments. But hydrogels offer two critical advantages:
Customization — They can be tuned to fit the biological and mechanical needs of each wound type.
Multifunctionality — One material can hydrate, protect, medicate, and guide healing at the same time.
The challenge is translation. While hundreds of promising hydrogel formulations exist in academic labs, very few make it through the testing, regulatory, and manufacturing hurdles to reach patients.
Final Thought
The chronic wound epidemic is growing — especially with rising rates of diabetes and aging populations. But the science is ready. With the right materials — and the right tools to test and optimize them — we can dramatically improve patient outcomes.
If you're working on wound care hydrogels or bringing a new material to market, I’d love to connect and hear what you're building.